Finally, in addition to breast cancer, the significance of our finding should be further studied also in other cancers where BPs are much used or where low tumor TLR9 expression is associated with poor outcome, such as renal cell carcinoma [64]. The gene discussed is TLR9; the disease is hereditary clear cell renal cell carcinoma.